A detailed history of Macquarie Group LTD transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 379,100 shares of RCUS stock, worth $6.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
379,100
Previous 379,100 -0.0%
Holding current value
$6.03 Million
Previous $5.77 Million 0.4%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 21, 2023

SELL
$19.7 - $35.71 $14,932 - $27,068
-758 Reduced 0.2%
379,100 $7.84 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $511 - $661
-22 Reduced 0.01%
379,858 $9.94 Million
Q4 2021

Feb 11, 2022

SELL
$31.38 - $48.47 $2.58 Million - $3.98 Million
-82,100 Reduced 17.77%
379,880 $15.4 Million
Q3 2021

Nov 12, 2021

SELL
$26.93 - $37.68 $38,186 - $53,430
-1,418 Reduced 0.31%
461,980 $16.1 Million
Q1 2021

May 14, 2021

BUY
$26.16 - $41.39 $27,049 - $42,797
1,034 Added 0.22%
463,398 $13 Million
Q3 2020

Nov 13, 2020

BUY
$17.14 - $25.47 $1.05 Million - $1.56 Million
61,200 Added 15.26%
462,364 $7.93 Million
Q2 2020

Aug 11, 2020

BUY
$13.97 - $36.56 $5.6 Million - $14.7 Million
401,164 New
401,164 $9.93 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.